国产又色又爽又黄的在线观看,一本大道东京热无码一区,蜜臀av一区二区三区不卡

首頁(yè)> 產(chǎn)品列表> 先導(dǎo)化合物目標(biāo)試劑>

Turoctocog alfa pegol

NMR下載 COA and HPLC MSDS下載
names：
Turoctocog alfa pegol
CAS號(hào)：
1309086-46-1
MDL Number：
MF(分子式)： MW(分子量)：
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫(kù)存描述	數(shù)量	總計(jì) (￥)
DBK502205-500mg	500mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00
DBK502205-100mg	100mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00

大包裝詢(xún)價(jià) 提供各種包裝，敬請(qǐng)垂詢(xún)
收藏商品商品點(diǎn)評(píng) 加入購(gòu)物車(chē) 立即購(gòu)買(mǎi)

快速詢(xún)價(jià)

收起

你想詢(xún)價(jià)的產(chǎn)品

*產(chǎn)品名稱(chēng)：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫(xiě)您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱(chēng)：

*電子郵箱：

聯(lián)系人：

*電話(huà)：

*驗(yàn)證碼：

詢(xún)價(jià)

中文別名	Turoctocog alfa pegol
英文別名	Turoctocog alfa pegol
CAS號(hào)	1309086-46-1
Inchi
InchiKey
分子式 Formula
分子量 Molecular Weight
溶解度Solubility
性狀	NA
儲(chǔ)藏條件 Storage conditions

Turoctocog alfa pegol使用注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過(guò)程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害。
3.取樣品的移液槍頭需及時(shí)更換，必要時(shí)為避免交叉污染盡可能選擇濾芯吸頭。
4.稱(chēng)量藥品時(shí)選用稱(chēng)量紙，并無(wú)風(fēng)處取藥和稱(chēng)量以免揚(yáng)撒，試劑的容器使用前務(wù)必確保干凈，并消毒。
5.取藥品時(shí)盡量采用多個(gè)藥勺分別使用，使用后清洗干凈。
6.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類(lèi)存儲(chǔ)，并交于專(zhuān)業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染。
大規(guī)格定制：定制產(chǎn)品請(qǐng)將信息發(fā)送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

產(chǎn)品說(shuō)明	Organic Acids
Introduction
Application1	The principal characteristic that defines hemophilia A is the limited presence or complete deficiency of human clotting factor VIII in the body5. Subsequently, because factor VIII is a critical component that is essential for the extrinsic tissue factor pathway of the blood coagulation cascade process to proceed, individuals with hemophilia A ultimately experience increased bleeding - in comparison to individuals without a factor VIII deficiency - after injury or any kind of medical procedure5. Such increased bleeding can be heavy and/or fatal and may occur due to minimal injury or even when there is no injury whatsoever - in which case the bleeding is spontaneous5. Furthermore, excessive bleeds that bleed into muscles, organs, and joints are also associated with dangerous complications and regular pain5.The turoctocog alfa pegol (N8-GP) drug is consequently recombinant factor VIII (rFVIII) in which specific site-directed glycoPEGylation has been performed in an effort to increase the half-life of the rFVIII moiety without altering its hemostatic activity1,2. In particular, the general rFVIII component of N8-GP is turoctocog alfa, a human coagulation factor VIII (rDNA), with a truncated B-domain1,2. This glycoprotein has the same structure as human clotting factor VIII when activated, and also possesses post-translational modifications that are similar to those of the plasma-derived molecule1,2.In blood, factor VIII predominantly circulates in a stable non-covalent complex with von Willebrand factor (vWF)3,6. Concurrently, the tyrosine sulfation site present at the Tyr1680 (native full length) position, which is important for binding to vWF, has been found to be fully sulfated in the turoctocog alfa molecule1,2. Subsequently, when infused into a hemophilia patient, this rFVIII binds to endogenous vWF in the patient’s circulation1,2. The resultant factor VIII/vWF complex consists of two molecules (factor VIII and vWF) with different physiological functions1,2,3,6. Factor VIII is activated by thrombin (factor IIa)1,2,5. Activated factor VIII acts as a co-factor for activated factor IX, accelerating the conversion of factor X to activated factor X5. Activated factor X converts prothrombin into thrombin5. Thrombin then converts fibrinogen into fibrin and a clot can be formed5. Turoctocog alfa pegol consequently functions predominantly as factor VIII replacement therapy for patients with factor VIII deficient hemophilia A.Finally, the particular N8-GP molecule has a 40-kDa polyethylene glycol (PEG) attached to a specificO-glycan in the truncated B-domain of the general turoctocog alfa rFVIII structure1,2. Upon activation by thrombin, this B-domain possessing the pegylation is cleaved away, leaving active rFVIIIa - which as discussed above, is highly similar to and elicits the same blood clotting activities as native factor VIII1,2. Subsequently, the PEG group of N8-GP ultimately serves to extend the half-life of the overall drug molecule in the body. As an inert chemical, the PEG group prolongs N8-GP's half-life by acting like an obstructive 'cloud' around the rFVIII molecule to which it is attached12. Since the PEG group is generally too large to be cleared by the kidneys and does not bind particularly well with the clearance receptors that typically eliminate endogenous factor VIII, N8-GP demonstrates a longer half-life than the general turoctocog alfa rFVIII structure12.TargetActionsOrganismACoagulation factor IXactivatorHumansACoagulation factor XactivatorHumansAProthrombinbinderHumans
Application2
Application3

警示圖
危險(xiǎn)性
危險(xiǎn)性警示	warning
安全聲明
安全防護(hù)
備注	實(shí)驗(yàn)過(guò)程中防止吸入、食如，做好安全防護(hù)